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RET activation in adult and childhood papillary thyroid carcinoma using a
reverse transcriptase-n-polymerase chain reaction approach on archival-
nested material
GH Williams, S Rooney, GA Thomas, G Cummins and ED Williams
Department ofHistopathology, University of Cambridge, Addenbrookes Hospital, Cambridge CB2 2QQ, UK.
Summary Activation of the RET tyrosine kinase domain occurs in a proportion of thyroid papillary
carcinomas. Three chromosomal rearrangements have been described, of which PTCJ is the commonest. Wide
differences (2.5-25%) in frequency ofPTCJ in different populations have been reported; it is not clear whether
these are due to environmental factors, racial differences or technical reasons. We have developed a simple and
rapid reverse transcriptase nested polymerase chain reaction (RT-nPCR) method enabling the detection ofgene
expression from single 5 pm sections of formalin-fixed paraffin wax-embedded archival material. We have
applied this approach to detect expression of the RET tyrosine kinase domain, allowing identification of RET
activation resulting from any rearrangement, whether characterised or not, or from overexpression. A
retrospective study was performed on 22 adult and 21 childhood papillary carcinomas. Thirteen of 22 (59%)
adult and 10 of 21 (48%) childhood carcinomas showed evidence of RET activation, demonstrating a major
role for the RET oncogene in UK thyroid papillary carcinogenesis. This study also shows a similar frequency
of RET activation in both children and adults. The use of a technique that allows reliable amplification of
RNA from archival material, using primers chosen in different exons so that amplified products are readily
distinguished from genomic DNA, will allow correlation of translocations and chromosomal rearrangements
with a variety of specific tumour types.
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Several neoplasms are associated with chromosomal translo-
cations or rearrangements that fuse two unrelated genes.
Whereas oncogene point mutations commonly occur in a
range of tumour types, translocations are often restricted to
specific tumour types, for example in the lymphomas and
leukaemias (Dalla-Favera et al., 1982; Bartram et al., 1983).
More recently translocations have been characterised in solid
tumours including sarcomas and here too they can be specific
for one morphological type, for example myxoid liposarco-
ma, alveolar rhabdomyosarcoma and Ewings sarcoma, each
with their own distinct fusion gene found in all or nearly all
tumours (Crozat et al., 1993; Galili et al., 1993; Zucman et
al., 1993; Schoenmakers et al., 1995). Other chromosomal
rearrangements such as the RET rearrangement (Pierotti et
al., 1992) although restricted to thyroid papillary carcinoma
have been found in only a proportion of cases. The
possibility that chromosomal translocations or rearrange-
ments may define tumours with different aetiologies,
morphology and clinical outcome needs to be explored.
The RET proto-oncogene encodes for a protein
structurally related to the transmembrane receptors with a
tyrosine kinase domain but its putative ligand is unknown
(Takahashi and Cooper, 1987; Takahashi et al., 1988). The
gene is expressed in a number of cell lineages of the
developing peripheral and central nervous system as well as
in the excretory system (Pachnis et al., 1993) and has been
described in three hereditary cancer syndromes (Donis-Keller
et al., 1993; Mulligan et al., 1993; Carlson et al., 1994; Eng
et al., 1994; Hofstra et al., 1994). RET proto-oncogene
expression has not been detected in normal follicular cells,
(Fabien et al., 1992), the cell of origin of papillary
carcinoma. Activation of the RET oncogene in papillary
carcinoma can occur by three different chromosomal
rearrangements. A fusion gene now designated RET/PTCJ
was initially reported by the Naples group in about 25% of
papillary carcinomas. It is formed by an intrachromosomal
rearrangement fusing the RET tyrosine kinase domain to the
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5' terminal region of another gene H4 (Grieco et al., 1990;
Pierotti et al., 1992). Other studies have reported different
frequencies of the RET/PTCJ rearrangement in papillary
carcinomas from different populations. Lower percentages
were noted in patients with papillary carcinomas from the
United States, Japan and Saudi Arabia with 11%, 9% and
2.5% respectively (Ishizaka et al., 1991; Jhiang et al., 1991;
Zou et al., 1994). However some of these studies involved
only relatively small numbers of cases, a limitation imposed
by the requirement for fresh tissue for molecular biological
analysis. Most of these studies appear to have examined
tumours from adults and make no reference to childhood
tumours. Two additional but less frequent forms of
chromosomal rearrangement have been reported with fusion
of the RET tyrosine kinase coding region to the amino
terminus of two other heterologous genes, the receptor for
cAMP type 1 in RET/PTC2 and ELEl in RET/PTC3
(Bongarzone et al., 1993; Santoro et al., 1994). In a series by
Bongarzone et al. (1994) all three rearrangements together
were found in 34% of papillary carcinomas.
The oncogene TRK has also been shown to be involved in
a small proportion of cases of papillary carcinoma, and
shows interesting parallels with RET. This is a tyrosine
kinase-linked receptor, its ligand is nerve growth factor. This
gene is also activated in papillary carcinoma by rearrange-
ment of the tyrosine kinase part of the gene (Greco et al.,
1992). Thyroid carcinoma is rare in childhood, forming 0.4%
of all paediatric malignancies in the UK (McWhirter et al.,
1989). However thyroid cancer in children is assuming greater
importance currently because ofreports of a greatly increased
incidence in children exposed to fall out in the areas around
Chernobyl (Baverstock et al., 1992; Kazakov et al., 1992;
Williams et al., 1993). We have therefore set out to establish
the frequency of RET activation in the UK in both adult and
childhood thyroid papillary carcinomas. We screened for
RET activation using a recently reported technique that we
have developed to analyse RNA transcripts from formalin-
fixed paraffin wax-embedded tissue, allowing retrospective
analysis of tumour specimens to be undertaken from the
hospital pathology archives (Williams and Williams, 1995).
We designed primers to detect the expression of the RETRET activation in thyroid carcinoma
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tyrosine kinase domain (TK), common to all the fusion
transcripts and therefore allowing detection of RET
activation through all forms of rearrangement
To establish the incidence of RET activation in a non-
radiation-exposed population of children as well as adults, we
have studied sections from archival paraffin blocks of an
unselected series of childhood thyroid papillary carcinomas
registered in England and Wales over a 30 year period
(Harach and Williams, 1995), and have screened these
tumours for RET activation together with a similar number
of adult tumours.
Materials and methods
Extraction ofRNAfromformalin-fixedparaffin wax-embedded
thyroid tumours
Twenty-two cases of adult papillary thyroid carcinoma were
randomly selected from the paraffin wax-embedded archives
within the department. Paraffin wax-embedded blocks of
childhood papillary carcinomas recorded in the UK over a 30
year period were requested from all hospitals where cases had
been operated. Twenty-one of these were randomly selected
for analysis.
Serial 5 pm sections of the tumour samples were cut and
mounted on glass slides. The microtome blade was
thoroughly cleaned between cases to prevent cross contam-
ination between samples through carry over. A 5 pm section
was stained with haematoxylin and eosin to confirm the
morphological diagnosis., Using a scalpel blade and
dissecting microscope, non-tumorous thyroid tissue was
removed from the slide. The section of tumour was
deparaffinised in two serial washes of xylene and two washes
of absolute alcohol, dried and then digested in 50 pl of
proteinase K digestion buffer consisting of 50 mM Tris (pH
8.3), 1 mM EDTA, 0.5% Tween 20 and 200 mg ml-1
proteinase K. Samples were incubated first for 3 h at 55°C
then 8 min at 95°C to inactivate the protease. Insoluble
material was pelleted by centrifugation and a reverse
transcriptase reaction was performed directly on an aliquot
of the supernatant. Identical techniques were applied to
paraffin sections of archival normal thyroid confirmed to be
tumour free by histological examination (12 cases) and to
paraffin sections of breast tissue with or without tumour
(twenty cases)
Mutations in the RET oncogene are known to lead to C
cell hyperplasia and neoplasia, and there is a theoretical
possibility that C cells would account for RET TK positivity
in the tumours examined. We have therefore carried out
immunocytochemistry for calcitonin to identify C cells in the
sections immediately adjacent to that chosen for analysis, and
have also removed all non-neoplastic thyroid from the
tumour sections analysed, using a dissecting microscope.
None of the tumours examined contained any C cells within
their substance.
RT-nPCR methodfor detecting expression of the RET YTK
The RNAcontained in 3 pl ofthe supernatant oftheproteinase
K digest was reverse transcribed directly into cDNA in a final
volume of25 pl containing 0.1 optical density units ofrandom
hexamers [Pharmacia P(N)6], 2.5 pl of 10 x RT buffer [1 x RT
50 mM Tris-HCL (pH 8.3), 50 mM potassium chloride, 4 mM
DTT, 10 mm magnesium chloride], 2.5 pl of 10 mM dNTPs, 1
unitpl RNasin and 200 units ml-' super RT and incubated at
41°C for 60 min. The reaction was terminated by heating to
95°C for 5 min. An aliquot of 15 pl ofthe reaction mixture was
used for PCR amplification with the first round outnested
primers 5'-caccggatggagaggccagacaactgcagc-3' and 5'-
accggccttttgtccgg-ctc-3'. An aliquot of 2 pl of the first round
PCR product was amplified in a second round PCR reaction
using in-nested primers 5'-gagaggccagacaactgcagc-3' and 5'-
ccttttgtccggctcct-gcttccagcattg-3. Primers were designed corre-
sponding to exon 16, 5' upstream and exon 17, 3' downstream,
spanning a 1150 bp intron (Figure 1). Both PCR reactions
consisted of35cycles ofamplification at 95°C for 30 s, 55°C for
30 s and 72°C for 1 min. The first and second round PCR
reactions were set up in different areas in the laboratory and
reagent preparations were carried out in Radleys UVIOO
genespheres. These spheres provide microenvironments in
which the work area is enclosed and supplied by filtered
positive pressure air. Following reagent preparation the
microenvironment is exposed to UV irradiation. Both these
measures were employed to exclude PCR contamination.
Parallel reagent negative controls were run with all samples
to exclude generalised PCR contamination. Breast tissue
together with normal thyroid tissue without C cells, both
negative for RET expression, were run in parallel to exclude
sporadic PCR contamination. An aliquot of20 pl ofeach PCR
reaction was run on a 15% non-denaturing polyacrylamide gel
together with 0X markers. Actin mRNA was chosen as a
reporter target for amplification to monitor the presence of
RNA in the paraffin wax-embedded sections, assuming that
negative amplification results would indicate RNA degrada-
tion. The primers 5'-gtggggcgccccaggcacca-3' and
ctcttgctctgggcctcgtc-3' were again chosen in different exons to
generate an 82 bp PCR product from mRNA and therefore
readily distinguished from actin gene amplification containing
a 131 bp intron. Thirty cycles ofamplification were performed
at 95°C for 30 s, 48°C for 30 s and 72°C for 1 min.
Sequencing analysis
The 5' upstream in-nested primer was biotinylated. For
tumours showing generation of a PCR product of the
predicted 76 bp size, the presence of RET activation was
confirmed by direct solid-phase sequencing. The biotinylated
PCR product was immobilised on streptavidin dynabeads M-
280 according to the manufacturers instructions (Dynal). The
immobilised product was sequenced using the United States
Biochemicals Sequenase version 2.0 kit and an internal
sequencing primer (5'-tttgtccggctcctgctt-3').
Results
Detection of the expression of the RET TK by the RT-nPCR
method
Twenty-two adult and 21 childhood papillary thyroid
carcinomas, together with 32 control tissues were screened
a
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Figure 1 (a) Diagrammatic exon structure of TK domain (M)
of the RET proto-oncogene showing the relative position of out-
nested primers (3096-3126 and 3166-3186), numbered from the
transcription start site as defined by Ito et al. (1992). The primers
were chosen for different exons resulting in PCR amplification of
a 1240bp product from genomic DNA. (b) Diagramatic
representation of the cDNA of the RET proto-oncogene,
showing the position of the same primers as in A, giving rise to
a 90bp first round PCR amplification product that forms the
template for a second round in-nested PCR amplification product
of 76bp. Amplification of genomic DNA is therefore easily
distinguished from the amplification of cDNA, because of a more
than 15-fold difference in product size.6 /7 8 9
< 76 b:)
Figure 2 Polyacrylamide gel showing RET activation in four of
six thyroid papillary carcinomas. Lanes 3,5,6 and 7 show positive
tumours as indicated by the presence of a PCR product of the
predicted 76bp size, lanes 4 and 8 show negative tumours. The
0X size marker is in lane 9 and all controls are negative (reagent
only and normal thyroid tissue in lanes 1 and 2 respectively). One
positive tumour also shows a non-specific band, slightly larger
than the 281 bp OX fragment. Non-specific PCR products are
occasionally seen following amplification of degraded nucleic acid
from formalin-fixed tissues. RNA was extracted from a 5gm
section of 43 tumour samples using a simple proteinase K
digestion method. Contaminating C cells, a possible source of
RET mRNA transcripts, were excluded from the samples by
microdissection following immunocytochemical staining for
calcitonin. After reverse transcription, a nested PCR was
performed.
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Table I RET expression in adult and childhood thyroid papillary
carcinoma
Sex ratio RET
No. Age range Median (M/F) expression
Adults 22 24-76 50 5:17 13 (59%)
Children 21 7-14 13 3:18 10 (47%)
Total 43 7-76 24 8:35 23 (53%)
2 3 4 5 6 7 8 9 10 11
82 hp
Figure 4 Polyacrylamide gel showing expression of ,B-actin in
eight of eight papillary thyroid carcinomas (lanes 3-10),
indicated by the presence of a PCR product of the predicted
82bp size. The OX marker is in lane 11. Lane 1 represents a
reagent negative control and lane 2 represents a tumour sample in
which the reverse transcriptase enzyme has been omitted from the
reaction mixture.
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Figure 3 Sequence analysis of the nPCR products confirms RET
activation by showing the specific cDNA RET tyrosine kinase
domain coding sequence.
for RET activation using the RT-nPCR method. A total of
13 of 22 adult and 10 of 21 childhood papillary carcinomas
showed RET activation proven by the presence of a PCR
product of the predicted size (Figure 2) and confirmed by the
identification of the specific cDNA RET TK sequence using
direct solid-phase sequencing (Figure 3). The results are
shown in Table I. To confirm that a negative result was due
neither to excessive RNA degradation nor failure of
extraction, a similar length of mRNA transcript from the
ubiquitously expressed ,B-actin gene was used as a reporter
target for amplification (Figure 4). Actin mRNA was
detected in all 43 tumours. None of the 32 control tissues
(12 normal thyroids and 20 breast tumours/normal breast)
showed RET activation.
Discussion
In this study we have shown that is is possible to extract
RNA from single sections of paraffin wax-embedded archival
material and to demonstrate gene expression by using primers
chosen for different exons and so generating a PCR product
spanning an intron.
Thyroid follicular cells do not normally express RET
(Fabien et al., 1992). However thyroid papillary carcinoma, a
tumour derived from the follicular cell, shows RET activation
through rearrangement, initially described with H4 to give an
oncogene now designated RET/PTCI (Grieco et al., 1990;
Pierotti et al., 1992), but later described with two additional
rearrangements, with a further rearrangement yet to be
characterised (Bongarzone et al., 1993; Santoro et al., 1994).
In this study we have therefore modified our previous
technique for the detection of the chimeric fusion transcript
RET/PTC] (Williams and Williams 1995) by designing
primers corresponding to the RET TK. This allows detection
of RET expression occurring through overexpression or any
form of rearrangement whether characterised or not.
Contaminating C cells, a possible source of RET mRNA
transcripts were carefully excluded from the tumour samples
for analysis by immunocytochemical staining for calcitonin, a
consistent product of C cells and microdissection.
We find activation of the RET oncogene in about half of
UK adult thyroid papillary carcinomas. Studies of tumours
of adults from the US, Japan, or Saudi populations found
PTCJ with a frequency ranging from 2.5% to 11% of
papillary carcinomas (Ishizaka et al., 1991; Jhiang et al.,
1991; Zou et al., 1994). In the Italian series (Bongarzone et
al., 1994), PTC] was the commonest rearrangement, but all
IRET activation in thyroid carcinoma
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three rearrangements together formed only 34% of the
papillary carcinomas studied. This is considerably less than
the 56% of adults in our study, and significantly (P<0.05)
less than the 23/40 (53.5%) in the combined adults and
children. Our previous study of 15 different papillary
carcinomas found that six (40%), showed PTCJ, again
higher than the Italian series, in which 19% of the tumours
showed PTCJ.
We are therefore detecting a slightly higher proportion of
RET TK expression than the proportion ofcases shown to be
due to RET rearrangements in other studies. The discrepancy
is not large, and we have excluded the possibility that it is
due to expression by C cells. Studies of larger numbers by
both our techniques using RET TK expression and the
separate identification of each of the known RET transloca-
tions are needed to determine whether there are a significant
number of cases with either unidentified RET rearrangements
or overexpression of RET from other mechanisms such as
gene amplification. It is also possible that the Southern blot
identification of rearrangements is relatively insensitive in
cases with a high stromal component. Both approaches agree
that there is a significant proportion of papillary carcinomas
that lack evidence of RET involvement, a minority of these
seem to be due to TRK rearrangements, other translocations
may yet remain to be identified. The studies of childhood
thyroid carcinoma show that the proportion of cases with
RET expression by RT-nPCR is similar to that in UK adults.
Ito et al. (1994) reported that of 20 cases of childhood
thyroid papillary carcinoma from the Chernobyl area, four
out of the seven that could be successfully analysed showed
the PTCJ translocation using RT-PCR. The observation was
interpreted as suggesting that the translocation might be
related to the radiation exposure. However no studies of
control children were reported. The proportion of positives
was very similar to that which we found by RT-nPCR of
PTCJ in non-irradiated adults (Williams and Williams, 1995)
and less than that found for RET expression by RT-nPCR in
non-irradiated children. The relationship of RET activation
to radiation exposure therefore remains to be proven.
The RT-nPCR method adopted in this study is potentially
of major importance in the elucidation of molecular
pathological mechanisms because it illustrates the possibility
of detecting a range of biologically interesting messenger
RNA molecules from single sections of paraffin wax-
embedded formalin-fixed tissue. This allows the biological
significance of newly discovered genes to be explored rapidly
even for rare tumours as in this study of childhood thyroid
tumours where tissue was analysed from blocks collected over
a 30 year period. Large retrospective studies can also be
performed. The method is particularly applicable to
determining the biological role of the recently discovered
chromosomal rearrangements/translocations giving rise to
chimeric fusion transcripts in a variety of solid tumours
(Galili et al., 1993; Crozat et al., 1993; Zucman et al., 1993;
Schoenmakers et al., 1995). Studies of these translocations
have usually been performed on only small numbers of
tumours because of the requirement for fresh tissue for
standard molecular biological studies. This method can be
applied to the large numbers of tumours in pathology
department archives allowing, for example, correlation of
translocations with morphological diagnosis, response to
therapy and survival.
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